Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 5/21/2007 First Published: 4/1/2002


1.		Phase III Randomized Study of Radical Radiotherapy With or Without Carbogen and Niacinamide in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Other				MTVERNHOSP-BCON EU-20051, NCT00033436


2.		Randomized Trial of ARCON in Larynx Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				19 and over				Other				098 CKTO 2000-09, NCT00147732

Last Modified: 6/1/1997


3.		Phase I/II Study of Accelerated Radiotherapy with Carbogen and Nicotinamide Radiosensitization (ARCON) in Patients with Glioblastoma (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				16 to 69								EORTC-22933

Last Modified: 6/1/1995


4.		Phase I/II Study of Accelerated Radiotherapy with Carbogen/Niacinamide Radiosensitization (ARCON) in Squamous Cell Head and Neck Cancer, Nonsmall Cell Lung Cancer, and Transitional Cell Carcinoma of the Bladder (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				under 70								EORTC-22923

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute